Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Sichuan Baili Pharmaceutical is the lead sponsor of 133 current clinical trials in our China register. 77 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Iza-bren, BL-M07D1 and SI-B003. The most-studied condition is Solid Tumor.

ClinicalTrials.gov trials by status

Recruiting7758%
Not yet open2116%
Active, closed3526%

Trials by phase

Phase 14534%
Phase 23526%
Phase 32720%
Phase 1/21814%
Phase 2/386%

Clinical trials sponsored by Sichuan Baili Pharmaceutical

133 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors NCT05470348 · Breast Cancer, Solid Tumor Drug: Iza-bren	Phase 1	Recruiting	2022-08	China
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) NCT07554456 · Esophageal Squamous Cell Carcinoma Drugs: Cisplatin, Ivonescimab, Iza-bren	Phase 2/3	Recruiting	2026-06	China
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors NCT06612840 · Non-small Cell Lung Cancer, Solid Tumor Drug: GNC-077	Phase 1	Recruiting	2024-10	China
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) NCT07648914 · Breast Cancer Drugs: Albumin-Bound Paclitaxel, Capecitabine, Iza-bren	Phase 3	Recruiting	2026-07	China
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors NCT06008054 · ClinicalTrials.gov ↗ · Esophageal Cancer, Gastric Cancer, Colorectal Cancer Drugs: Iza-bren, SI-B003	Phase 2	Recruiting	2023-11	China
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor NCT05262491 · ClinicalTrials.gov ↗ · Gastrointestinal Tumor Drug: Iza-bren	Phase 1	Recruiting	2022-02	China
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors NCT05461768 · ClinicalTrials.gov ↗ · Breast Cancer, Locally Advanced or Metastatic Solid Tumor Drug: BL-M07D1	Phase 1	Recruiting	2022-08	China
A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer NCT06498986 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Iza-bren, Osimertinib	Phase 2	Recruiting	2024-07	China
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors NCT06006169 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma Drugs: Iza-bren, SI-B003	Phase 2	Recruiting	2023-10	China
A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies NCT06131450 · ClinicalTrials.gov ↗ · Gynecological Malignancies	Phase 1/2	Recruiting	2024-02	China
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus NCT06857214 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus Drugs: Belimumab, GNC-038	Phase 1	Recruiting	2025-06	China
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors NCT05785039 · ClinicalTrials.gov ↗ · Urinary System Tumor, Solid Tumor Drug: Iza-bren	Phase 2	Recruiting	2023-04	China
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer NCT07654400 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer Drugs: Atezolizumab, BL-M14D1	Phase 2	Recruiting	2026-07	China
A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08) NCT07640789 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage III Drugs: Iza-bren, Osimertinib	Phase 3	Recruiting	2026-08	China
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer NCT07054567 · ClinicalTrials.gov ↗ · Cervical Cancer, Endometrial Cancer	Phase 2	Recruiting	2025-08	China
A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer NCT07678957 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: BL-M07D1, Trastuzumab deruxtecan	Phase 2	Recruiting	2026-08	China
A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors NCT06493864 · ClinicalTrials.gov ↗ · Breast Cancer, Solid Tumor Drug: BL-B16D1	Phase 1	Recruiting	2024-08	China
A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors NCT06718621 · ClinicalTrials.gov ↗ · Solid Tumor Drug: BL-M08D1	Phase 1	Recruiting	2025-02	China
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer NCT06437509 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer Drug: Iza-bren	Phase 2	Recruiting	2024-06	China
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors NCT05956587 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma Drugs: Iza-bren, SI-B003	Phase 2	Recruiting	2024-01	China
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT05623982 · ClinicalTrials.gov ↗ · Non-hodgkin's Lymphoma Drug: GNC-038	Phase 1/2	Recruiting	2022-09	China
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors NCT07753226 · ClinicalTrials.gov ↗ · Breast Cancer, Solid Tumor Drug: SI-B036	Phase 1	Recruiting	2026-08	China
A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer NCT06978114 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Cancer	Phase 2	Recruiting	2025-06	China
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC NCT07178795 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer Drugs: BL-M07D1, Carboplatin, Cisplatin	Phase 3	Recruiting	2025-09	China
A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies NCT06066203 · ClinicalTrials.gov ↗ · Non-hodgkin's Lymphoma	Phase 1/2	Recruiting	2023-11	China
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer NCT06957886 · ClinicalTrials.gov ↗ · HER2-low Breast Cancer Drugs: Albumin paclitaxel, BL-M07D1	Phase 3	Recruiting	2025-05	China
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer NCT06471205 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer Drug: Iza-bren	Phase 2	Recruiting	2024-08	China
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma NCT07152405 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Drug: BL-M07D1	Phase 3	Recruiting	2025-09	China
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma NCT06598787 · ClinicalTrials.gov ↗ · Recurrent Glioblastoma Drug: Iza-bren	Phase 2	Recruiting	2024-10	China
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure NCT07606599 · ClinicalTrials.gov ↗ · Biliary Tract Cancer Drugs: BL-M07D1, Calcium levofolinate, Capecitabine	Phase 3	Recruiting	2026-07	China
A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors NCT06475131 · ClinicalTrials.gov ↗ · Solid Tumor Drug: BL-B16D1	Phase 1	Recruiting	2024-07	China
A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors NCT06469008 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinomas, Solid Tumor Drug: BL-B16D1	Phase 1	Recruiting	2024-06	China
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment NCT07518147 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Drugs: BL-M05D1, Docetaxel, Irinotecan Hydrochloride	Phase 3	Recruiting	2026-05	China
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01) NCT07582315 · ClinicalTrials.gov ↗ · Biliary Tract Cancer Drugs: Calcium levofolinate, Capecitabine, Fluorouracil	Phase 3	Recruiting	2026-06	China
A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy NCT06830889 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer Drugs: BL-M07D1, Trastuzumab emtansine	Phase 3	Recruiting	2025-06	China
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors NCT07678970 · ClinicalTrials.gov ↗ · Gastrointestinal Tumor, Solid Tumor Drug: SI-B036	Phase 1	Recruiting	2026-07	China
Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors NCT05631964 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Digestive Tract Tumors, Other Solid Tumors	Phase 1	Recruiting	2023-01	China
A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia NCT07255872 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia Drugs: Azacitidine, BL-M11D1, Cytarabine	Phase 2/3	Recruiting	2026-04	China
A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer NCT06042894 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Iza-bren, SI-B003	Phase 2	Recruiting	2023-12	China
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) NCT06994195 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Drugs: Iza-bren, Topotecan	Phase 3	Recruiting	2025-08	China
A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors NCT07591155 · ClinicalTrials.gov ↗ · Solid Tumors Drug: BL-ARC002	Phase 1	Recruiting	2026-05	China
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies NCT05990803 · ClinicalTrials.gov ↗ · Cervical Cancer Drugs: Iza-bren, SI-B003	Phase 2	Recruiting	2023-11	China
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) NCT07502300 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer Drugs: Carboplatin, Etoposide, Iza-bren	Phase 3	Recruiting	2026-06	China
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors NCT06609187 · ClinicalTrials.gov ↗ · Breast Cancer, Solid Tumor Drug: GNC-077	Phase 1	Recruiting	2024-10	China
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01) NCT06857175 · ClinicalTrials.gov ↗ · Urothelial Carcinoma Drugs: Docetaxel, Iza-bren, Paclitaxel	Phase 3	Recruiting	2025-03	China
A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors NCT06031584 · ClinicalTrials.gov ↗ · Her2-positive/Low-expression Urinary and Digestive Tract Tumors Drug: BL-M07D1	Phase 1/2	Recruiting	2024-01	China
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors NCT06505824 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer, Neuroendocrine Tumors Drug: BL-M14D1	Phase 1	Recruiting	2024-08	China
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC NCT07264816 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer Drugs: BL-M07D1, Pembrolizumab	Phase 2	Recruiting	2026-02	China
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors NCT06475300 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Solid Tumor Drugs: Iza-bren, Pemetrexed Disodium	Phase 2	Recruiting	2024-06	China
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor NCT05194982 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumor	Phase 1	Recruiting	2021-11	China
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer NCT07518173 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer Drugs: BL-M07D1, Docetaxel, Pertuzumab	Phase 3	Recruiting	2026-04	China
A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies NCT06718634 · ClinicalTrials.gov ↗ · Relapsed or Refractory Lymphoid Malignancies Drug: BL-M08D1	Phase 1	Recruiting	2025-01	China
A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer NCT06891833 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2/3	Recruiting	2025-06	China
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors NCT07274852 · ClinicalTrials.gov ↗ · Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma Drug: Lutetium [177Lu] BL-ARC001	Phase 1	Recruiting	2025-12	China
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors NCT06954077 · ClinicalTrials.gov ↗ · Gastrointestinal Tumor, Solid Tumor Drug: BL-M09D1	Phase 1	Recruiting	2025-05	China
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies NCT07255898 · ClinicalTrials.gov ↗ · Multiple Myeloma, Hematologic Malignancies Drug: BL-M24D1	Phase 1	Recruiting	2026-03	China
A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors NCT06349811 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors Drug: BL-M05D1	Phase 1	Recruiting	2024-04	China
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT05924750 · ClinicalTrials.gov ↗ · Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Drug: BL-M11D1	Phase 1	Recruiting	2023-08	China
A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors NCT07232407 · ClinicalTrials.gov ↗ · Gastrointestinal Tumors, Solid Tumors Drug: Lutetium [177Lu] BL-ARC001	Phase 1	Recruiting	2025-11	China
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors NCT07056556 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, Solid Tumor Drug: BL-M09D1	Phase 1	Recruiting	2025-07	China
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis NCT06857227 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis Drug: GNC-038	Phase 1	Recruiting	2025-03	China
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors NCT07232524 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Solid Tumor Drug: BL-M24D1	Phase 1	Recruiting	2025-12	China
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors NCT06500052 · ClinicalTrials.gov ↗ · Esophageal Cancer, Gastric Cancer, Pancreatic Cancer Drug: BL-M17D1	Phase 1	Recruiting	2024-07	China
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer NCT05924841 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 2	Recruiting	2023-11	China
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer NCT06962787 · ClinicalTrials.gov ↗ · Renal Cancer Drugs: Axitinib, Iza-bren, Lenvatinib	Phase 2	Recruiting	2025-07	China
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors NCT06503783 · ClinicalTrials.gov ↗ · Breast Cancer, Solid Tumor Drug: BL-M17D1	Phase 1	Recruiting	2024-08	China
A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma NCT06986785 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma	Phase 2	Recruiting	2025-06	China
A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) NCT07642024 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Iza-bren	Phase 2/3	Recruiting	2026-07	China
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors NCT06437522 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma Drug: Iza-bren	Phase 2	Recruiting	2024-06	China
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors NCT07279428 · ClinicalTrials.gov ↗ · Gastrointestinal Tumors, Solid Tumors Drug: BL-M24D1	Phase 1	Recruiting	2026-01	China
A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma NCT06405425 · ClinicalTrials.gov ↗ · Urothelial Carcinoma Drugs: Iza-bren, PD-1	Phase 2	Recruiting	2024-05	China
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Solid Tumors NCT07606612 · ClinicalTrials.gov ↗ · Solid Tumor Drug: SI-B036	Phase 1	Recruiting	2026-06	China
A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors NCT04794972 · ClinicalTrials.gov ↗ · Recurrent Glioma, Solid Tumor	Phase 1	Recruiting	2021-04	China
A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04) NCT06838273 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Iza-bren, Osimertinib	Phase 3	Recruiting	2025-02	China
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors NCT05965856 · ClinicalTrials.gov ↗ · Urothelial Carcinoma, Solid Tumor Drugs: Iza-bren, SI-B003	Phase 2	Recruiting	2023-12	China
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors NCT07232420 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Solid Tumor Drug: BL-M24D1	Phase 1	Recruiting	2025-11	China
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies NCT05803018 · ClinicalTrials.gov ↗ · Gynecological Malignant Tumor, Solid Tumor Drug: Iza-bren	Phase 1/2	Recruiting	2023-06	China
A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02) NCT07783321 · Nasopharyngeal Carcinoma (NPC) Drugs: Cisplatin, Gemcitabine, Iza-bren	Phase 3	Not yet open	2026-09	China
A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05) NCT07739199 · ClinicalTrials.gov ↗ · Squamous Non-small-cell Lung Cancer Drugs: Carboplatin, Iza-bren, Paclitaxel	Phase 2/3	Not yet open	2026-08	China
A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) NCT07729956 · ClinicalTrials.gov ↗ · Triple-Negative Breast Cancer (TNBC) Drugs: Iza-bren, Nab-paclitaxel	Phase 3	Not yet open	2026-08	China
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gynecological Tumors and Other Solid Tumors NCT07778862 · ClinicalTrials.gov ↗ · Gynecological Tumors, Solid Tumors Drug: SI-B036	Phase 1	Not yet open	2026-09	China
A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma NCT07797881 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC) Drugs: Cisplatin, Gemcitabine, Iza-bren	Phase 2	Not yet open	2026-09	China
A Study of BL-M08D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors NCT07788950 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinomas, Solid Tumors Drug: BL-M08D1	Phase 2	Not yet open	2026-09	China
A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes NCT07591168 · ClinicalTrials.gov ↗ · Myelodysplastic Syndromes Drug: BL-M11D1	Phase 1/2	Not yet open	2026-09	China
A Study of BL-M08D in Patients With Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors NCT07780318 · ClinicalTrials.gov ↗ · Gastrointestinal Tumors, Solid Tumors Drug: BL-M08D1	Phase 1/2	Not yet open	2026-09	China
A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer NCT07545460 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Drugs: BL-M07D1, Liposomal doxorubicin, Paclitaxel	Phase 3	Not yet open	2026-07	China
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors NCT06755242 · ClinicalTrials.gov ↗ · Gastrointestinal Tumors, Solid Tumor Drug: GNC-077	Phase 1	Not yet open	2025-01	China
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Head and Neck Tumors and Other Solid Tumors NCT07763639 · ClinicalTrials.gov ↗ · Head and Neck Tumors, Solid Tumors Drug: SI-B036	Phase 1	Not yet open	2026-08	China
A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer NCT07641855 · ClinicalTrials.gov ↗ · Castration-resistant Prostate Cancer Drugs: Abiraterone, Iza-bren, Olaparib	Phase 2/3	Not yet open	2026-09	China
A Study of BL-M08D1 in Patients With Recurrent or Metastatic Gynecological Malignancies and Other Solid Tumors NCT07793825 · ClinicalTrials.gov ↗ · Gynecological Tumors, Solid Tumors Drug: BL-M08D1	Phase 1/2	Not yet open	2026-09	China
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors NCT07744243 · ClinicalTrials.gov ↗ · Urological Cancer, Solid Cancer Drug: SI-B036	Phase 1	Not yet open	2026-08	China
A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT07827261 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Glecirasib, Iza-bren	Phase 2	Not yet open	2026-09	China
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gynecological Malignancies and Other Solid Tumors NCT07769229 · ClinicalTrials.gov ↗ · Gynecological Malignancies, Solid Tumors Drug: BL-M09D1	Phase 2	Not yet open	2026-08	China
A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma NCT07818499 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma Drugs: BL-M08D1, Cyclophosphamide, Doxorubicin Hydrochloride Liposome	Phase 1/2	Not yet open	2026-09	China
A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) NCT07739186 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Iza-bren	Phase 2/3	Not yet open	2026-08	China
A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan NCT07730489 · ClinicalTrials.gov ↗ · Colorectal Cancer Drugs: BL-M07D1, Fruquintinib, Regorafenib	Phase 3	Not yet open	2026-08	China
A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors NCT07763652 · ClinicalTrials.gov ↗ · Gastrointestinal Tumors, Solid Tumors Drug: BL-ARC002	Phase 1	Not yet open	2026-08	China
A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors NCT07818486 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC), Solid Tumors Drug: BL-M08D1	Phase 1/2	Not yet open	2026-09	China
A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma NCT06423885 · HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma Drug: BL-M07D1	Phase 2	Active, closed	2024-12	China
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors NCT05393427 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors Drug: Iza-bren	Phase 1	Active, closed	2022-02	China

Showing the 100 most recently updated of 133 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Sichuan Baili Pharmaceutical trials

70 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 30 more in the trial list above.

Conditions in Sichuan Baili Pharmaceutical trials

83 conditions

Solid Tumor23 Non-small Cell Lung Cancer15 Breast Cancer12 Solid Tumors12 Head and Neck Squamous Cell Carcinoma7 Gastrointestinal Tumors5 HER2-positive Breast Cancer5 Nasopharyngeal Carcinoma (NPC)3 Gastric Cancer3 Colorectal Cancer3Gastrointestinal Tumor3Extensive-stage Small-cell Lung Cancer3 Nasopharyngeal Carcinoma3 Non-squamous Non-small Cell Lung Cancer3 Urothelial Carcinoma3 Small Cell Lung Cancer3 Esophageal Squamous Cell Carcinoma2 Esophageal Cancer2Other Solid Tumors2Locally Advanced or Metastatic Solid Tumor2Gynecological Tumors2Gynecological Malignancies2Head and Neck Squamous Cell Carcinomas2Cervical Cancer2

By trial register

Register	Trials	Recruiting
Clinical trials in China	133	77

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Solid Tumor

Sponsor	Trials
Suzhou Suncadia Biopharmaceuticals	4
Peking University Cancer Hospital & Institute	3
Chinese PLA General Hospital	3
Shenzhen Geno-Immune Medical Institute	3
Shanghai Cell Therapy Group	3
Hua Zhu	3
Pyxis Oncology	2
Tyra Biosciences	2
Biohaven Therapeutics	2
Astellas Pharma	2

Sponsors with the most current trials registered for this condition.

Questions about Sichuan Baili Pharmaceutical trials

How many clinical trials does Sichuan Baili Pharmaceutical sponsor?

Sichuan Baili Pharmaceutical is the lead sponsor of 133 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Sichuan Baili Pharmaceutical trials recruiting?

Yes. 77 of its 133 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Sichuan Baili Pharmaceutical testing?

Its current trials name 70 drugs and biologicals as interventions. The most frequent are Iza-bren (42), BL-M07D1 (16), SI-B003 (10), SI-B001 (9) and BL-M08D1 (7). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Sichuan Baili Pharmaceutical clinical trials